Form 4 for ATTO Attovia Therapeutics, Inc.
Accepted 2026-08-06 17:35:51 ET · period of report 2026-08-06 · accession 0001231919-26-000838 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-06 17:35 | 2026-08-06 | ATTO | Frazier Life Sciences XI, L.P. | 10% | C - Cnv Deriv | — | +5.49M | 5.57M | +7,287% | — |
| D | 2026-08-06 17:35 | 2026-08-06 | ATTO | Frazier Life Sciences XI, L.P. | 10% | P - Purchase | $17.00 | +588.2K | 6.15M | +11% | +$10.00M |
| DM | 2026-08-06 17:35 | 2026-08-06 | ATTO | Frazier Life Sciences XI, L.P. | 10% | C - Cnv Deriv | $0.00 | -51.01M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-06 | C | A | 1,749,192 | — | 1,824,541 | D | — | — | (F1) The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date. (F2) The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. |
| 2 | Common | Common Stock | 2026-08-06 | C | A | 1,590,175 | — | 3,414,716 | D | — | — | (F3) The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F2) The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. |
| 3 | Common | Common Stock | 2026-08-06 | C | A | 1,189,940 | — | 4,604,656 | D | — | — | (F4) The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F2) The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. |
| 4 | Common | Common Stock | 2026-08-06 | C | A | 961,322 | — | 5,565,978 | D | — | — | (F5) The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F2) The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. |
| 5 | Common | Common Stock | 2026-08-06 | P | A | 588,235 | $17.00 | 6,154,213 | D | — | — | (F2) The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. |
| 6 | Derivative | Series A-1 Preferred Stock | 2026-08-06 | C | D | 16,250,000 | $0.00 | 0 | D | — · — to — | 1,749,192 Common Stock | (F1) The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date. (F1) The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date. (F1) The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date. (F2) The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. |
| 7 | Derivative | Series A-2 Preferred Stock | 2026-08-06 | C | D | 14,772,727 | $0.00 | 0 | D | — · — to — | 1,590,175 Common Stock | (F3) The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F3) The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F3) The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F2) The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. |
| 8 | Derivative | Series B Preferred Stock | 2026-08-06 | C | D | 11,054,544 | $0.00 | 0 | D | — · — to — | 1,189,940 Common Stock | (F4) The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F4) The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F4) The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F2) The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. |
| 9 | Derivative | Series C Preferred Stock | 2026-08-06 | C | D | 8,930,685 | $0.00 | 0 | D | — · — to — | 961,322 Common Stock | (F5) The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F5) The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F5) The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date. (F2) The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. |